决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors.
NR4A因子通过线粒体基因表达调控CAR-T细胞的持久性和干性,因此NR4A是生成针对实体瘤的优质CAR-T细胞的高度有前景的靶点。
嵌合抗原受体(CAR)-T 细胞对实体瘤的抗肿瘤效果受到多种因素的限制,例如浸润率低、扩增能力差以及肿瘤内 T 细胞的耗竭。NR4A 转录因子已在小鼠中被证明在 T 细胞耗竭中发挥重要作用。然而,每种 NR4a 因子对人 T 细胞分化的确切贡献仍待阐明。
在本研究中,我们利用 CRISPR/Cas9 系统敲除了识别人表皮生长因子受体2型 (HER2) 的人 CAR-T 细胞中的 NR4A 家族因子 NR4A1、NR4A2 和 NR4A3。我们通过将 CAR-T 细胞与 Her2 + A549 肺腺癌细胞反复共培养,在体外诱导这些细胞发生 T 细胞耗竭,并评估了细胞表面标志物(如记忆和耗竭表型)、增殖能力、细胞因子产生和代谢活性。我们通过将 CAR-T 细胞转移至 A549 荷瘤免疫缺陷小鼠体内,在体内验证了 NR4A1/2/3 三重敲除 (TKO) CAR-T 细胞的抗肿瘤毒性。
人 NR4A-TKO CAR-T 细胞在体外对反复抗原刺激诱导的耗竭具有抵抗性,与对照 CAR-T 细胞相比,在体外和体内均保持更高的杀瘤活性。对 NR4A 单敲、双敲和三敲有效性的比较表明,三敲在避免耗竭方面最为有效。此外,在包括老年人在内的多种供者来源的 T 细胞中,也观察到 NR4A TKO 对抗肿瘤效应的显著增强。在机制上,NR4A TKO CAR-T 细胞表现出增强的线粒体氧化磷酸化,因此能够在肿瘤内持续存在更长时间。
BACKGROUND: Antitumor effect of chimeric antigen receptor (CAR)-T cells against solid tumors is limited due to various factors, such as low infiltration rate, poor expansion capacity, and exhaustion of T cells within the tumor. NR4A transcription factors have been shown to play important roles in T-cell exhaustion in mice. However, the precise contribution of each NR4a factor to human T-cell differentiation remains to be clarified. METHODS: In this study, we deleted NR4A family factors, NR4A1 , NR4A2, and NR4A3, in human CAR-T cells recognizing human epidermal growth factor receptor type 2 (HER2) by using the CRISPR/Cas9 system. We induced T-cell exhaustion in these cells in vitro through repeated co-culturing of CAR-T cells with Her2 + A549 lung adenocarcinoma cells and evaluated cell surface markers such as memory and exhaustion phenotypes, proliferative capacity, cytokine production and metabolic activity. We validated the antitumor toxicity of NR4A1/2/3 triple knockout (TKO) CAR-T cells in vivo by transferring CAR-T cells into A549 tumor-bearing immunodeficient mice. RESULTS: Human NR4A-TKO CAR-T cells were resistant against exhaustion induced by repeated antigen stimulation in vitro, and maintained higher tumor-killing activity both in vitro and in vivo compared with control CAR-T cells. A comparison of the effectiveness of NR4A single, double, and TKOs demonstrated that triple KO was the most effective in avoiding exhaustion. Furthermore, a strong enhancement of antitumor effects by NR4A TKO was also observed in T cells from various donors including aged persons. Mechanistically, NR4A TKO CAR-T cells showed enhanced mitochondrial oxidative phosphorylation, therefore could persist for longer periods within the tumors. CONCLUSIONS: NR4A factors regulate CAR-T cell persistence and stemness through mitochondrial gene expression, therefore NR4A is a highly promising target for the generation of superior CAR-T cells against solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。